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Abstract
Introduction. Hip replacement (HR) operations are increasing. Short term mortality is 
an indicator of quality; few studies include risk adjustment models to predict HR out-
comes. We evaluated in-hospital and 30-day mortality in hospitalized patients for HR 
and compared the performance of two risk adjustment algorithms.
Materials and methods. A retrospective cohort study on hospital discharge records of 
patients undergoing HR from 2000 to 2005 in Tuscany Region, Italy, applied All-Patient 
Refined Diagnosis Related Groups (APR-DRG) and Elixhauser Index (EI) risk adjust-
ment models to predict outcomes. Logistic regression was used to analyse the perfor-
mance of the two models; C statistic (C) was used to define their discriminating ability.
Results. 25 850 hospital discharge records were studied. In-hospital and 30-day crude 
mortality were 1.3% and 3%, respectively. Female gender was a significant (p < 0.001) 
protective factor under both models and had the following Odds Ratios (OR): 0.64 for 
in-hospital and 0.51 for 30-day mortality using APR-DRG and 0.55 and 0.48, respec-
tively, with EI. Among EI comorbidities, heart failure and liver disease were associated 
with in-hospital (OR 9.29 and 5.60; p < 0.001) and 30-day (OR 6.36 and 3.26; p < 0.001) 
mortality. Increasing age and APR-DRG risk class were predictive of all the outcomes. 
Discriminating ability for in-hospital and 30-day mortality was reasonable with EI (C 
0.79 and 0.68) and good with APR-DRG (C 0.86 and 0.82).
Conclusions. Our study found that gender, age, EI comorbidities and APR-DRG risk 
of death are predictive factors of in-hospital and 30-day mortality outcomes in patients 
undergoing HR. At least one risk adjustment algorithm should always be implemented 
in patient management. 
INTRODUCTION
Total hip replacement was introduced in the 1960s 
and revolutionized management of elderly patients 
crippled with arthritis, showing very good long term re-
sults. Over the years it has developed into one of the 
most successful treatments in modern medicine [1, 2]. 
It improves function, reduces pain and increases over-
all performance in daily activities, improving patients’ 
quality of life [3-5]. In the past, indications for HR were 
restricted to the elderly, infirm or locomotor activity 
limited; today, unacceptable deterioration of quality of 
life is a valid indication for HR (even among younger 
patients). Better devices and minimally invasive surgery 
facilitate and accelerate discharge and rehabilitation. 
Patients seek so-called high performance hips to meet 
their expectations and aspirations [1]. As a consequence 
of demographic changes and procedural safety, hip re-
placement will see a significant numerical increase in 
the near future [4, 6]. It is therefore essential to assess 
the risk factors associated with higher mortality for bet-
ter peri-operative patient management [4, 7-10]. Bet-
ter risk stratification adjustment is essential to obtain 
quality improvement, to offer payer and patient indi-
cators of orthopaedic surgery quality, to better allocate 
hospital resources and to improve the predictability of 
HR outcomes [9, 11]. Mortality associated with HR is 
an acknowledged indicator of orthopaedic surgery qual-
ity [12]. Though low, mortality after hip replacement 
[4, 9, 12] is an objective event that must be evaluated 
because of the large number of operations performed 
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in the world and the importance of predictive factors 
for outcome. Several studies have shown that dementia, 
renal disease, cerebrovascular disease and diabetes are 
associated with mortality after HR [9]. Risk adjustment 
seems to be an effective and useful tool for proper com-
parisons, especially if we have to evaluate quality im-
provement. Risk adjustment is used in hospital quality 
and efficiency reports, and as frequent input for health 
plan capitation calculations. These are increasingly 
used for measuring and reporting the performance of 
physicians and various health treatments [13-15]. Since 
few studies have used risk adjustment in evaluating in 
HR outcomes, the aims of this study were: i) to evaluate 
in-hospital and 30-day mortality of HR patients; ii) to 
investigate and compare the ability and performance of 
two risk adjustment tools to predict our outcomes.
MATERIALS AND METHODS
Settings
We studied the hospital discharge records in a ret-
rospective cohort of patients undergoing HR surgery 
from 2000 to 2005 in twelve local and three university 
hospitals in Tuscany (Italy). We chose this period due 
to the availability of complete data related to the hos-
pital discharges of these patients. Every Local Health 
Unit has at least one hospital for general care. Tuscan 
hospitals belong to three Health Areas, HA1, HA2 
and HA3, measuring 4845, 6588 and 11 561 km2 with 
population densities of 319, 189 and 70 persons/km2, 
respectively [15]. 
Data sources and criteria selection
Using hospital discharge records and diagnosis/treat-
ment data, we selected the following inclusion/exclusion 
criteria: at least one primary surgery code for total hip 
replacement (procedure ICD code 81.51) or partial hip 
replacement (procedure ICD code 81.52), or revision 
of hip replacement (ICD 81.53), classificated as “re-
placement of hip joint” according to All-Patient Refined 
Diagnosis Related Group (APR-DRG) (code 301) but 
excluding hospitalizations with procedures having codes 
ICD 81.51 and ICD 81.53 or ICD 81.52 and ICD 81.53. 
The outcomes evaluated were: i) in-hospital mortality: 
patients who died during the case index hospitalization; 
ii) 30-day mortality: patients who died in or out of hospi-
tal within 30 days of surgery. We considered the general 
in-hospital and 30-day mortality after Hip replacement 
and not those of each subcategory of surgery (total, par-
tial or revision), because patients are already stratified by 
APR-DRG. In fact, this tool stratifies each case on the 
base of DRG (which consider the general group of “hip 
joint replacement”), primary and secondary diagnoses, 
age and procedures. Moreover, further stratifications by 
subgroups of surgery would reduce the sample size of 
each one with consequences on the inferential analysis. 
For the Elixhauser Index (EI), comorbidities are evalu-
ated from the diagnosis in the hospital discharge records 
and diagnosis-related groups of the last three years.
Tools
Two risk adjustment tools were used to predict out-
comes: All-Patient Refined Diagnosis Related Groups 
(APR-DRG) and Elixhauser Index (EI). APR-DRG 
is an admissions classification system which stratifies 
by iso-severity. Among the descriptors there are two 
measures related to severity of illness, i.e. the extent 
of physiologic decompensation or organ system loss of 
function, and risk of death (ROD), i.e. the likelihood 
of dying. These two measures vary from 1 (minor) to 
4 (extreme risk) and refer to diseases and procedures 
in the hospital discharge records [16, 17]. The other 
tool was EI, a set of measurements indicating 30 cat-
egories of comorbidity. Each comorbidity category is 
dichotomized: present/absent. Outcomes are related 
to the presence of comorbidities and worsen as they 
increase [18]. 
Statistical analysis
Descriptive analysis by age, ROD and gender was 
performed for in-hospital and 30-day mortality. We 
used logistic regression to find the best fitting and most 
parsimonious clinically interpretable model describing 
the relationship between outcomes and a set of inde-
pendent (predictors) variables [19]. The performance 
of the models was assessed by measures of calibration 
using the Hosmer-Lemeshow (HL) method and the 
area under the ROC curve. Discrimination indicates 
model ability to recognize outcomes from the predic-
tors; calibration measures the distance between pre-
dicted and observed values. We also compared 30-day 
mortality, crude and adjusted with the EI and APR-
DRG models, between university and local hospitals. 
The analysis was performed with STATA software 10.0 
(Data Analysis and Statistical Software. Copyright 
1996-2013 StataCorp LP). Statistical significance was 
set at p < 0.05.
RESULTS
The number of hospitalizations for hip replacements 
in the period 2000-2005 was 26 277. After applying the 
inclusion/exclusion criteria described above, we finally 
evaluated 25 850 cases, 83% of whom were patients 
over 65 years of age and 70% of whom were females. 
Ninety nine percent of cases had a minor or moderate 
ROD (Table 1). Among these patients, comorbidities 
were generally not very frequent: 3.4% had diabetes and 
only 1.6% had chronic lung disease.
Females were significantly less likely to die in hospi-
tal, OR = 0.64 (95% CI: 0.50-0.81; p < 0.001), or with-
in 30 days, OR = 0.51 (CI: 0.44-0.61; p < 0.001). For 
ROD in class 2 we found an OR of 7.40 (CI: 5.62-9.63; 
p < 0.001) for in-hospital mortality and 4.94 (CI: 4.05-
6.03; p < 0.001) for 30-day mortality. ROD in classes 3 
and 4, which were combined due to the small number 
of individuals, was strongly associated with in-hospital 
mortality (OR = 49.70; CI: 36.24-68.10; p < 0.001) and 
30-day mortality (OR = 28.67; CI: 21.59-38.08; p < 
0.001). Age was significantly associated with in-hospital 
and 30-day mortality and the strength of this associa-
tion increased with age, from OR = 2.54 (CI: 1.05-6.14; 
p = 0.039) and OR = 2.39 (CI: 1.38-4.14; p = 0.002) for 
ages 65-74, to OR = 18.20 (7.96-41.43; p < 0.001) and 
OR = 19.62 (CI: 11.79-32.63; p < 0.001) for ages > 85, 
respectively (Table 2). 
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The Elixhauser Index also associated age and gender 
with in-hospital and 30-day mortality. It estimated the 
role of the following comorbidities for in-hospital mor-
tality: heart failure with an OR of 9.29 (CI: 6.09-14.17; 
p < 0.001) and liver disease with an OR of 5.60 (CI: 
2.84-11.05; p < 0.001). Chronic pulmonary diseases 
and diabetes were also related to in-hospital and 30-day 
mortality with an OR of 2.11 (CI: 1.31-3.42; p < 0.001) 
and OR = 1.85 (CI: 1.20-2.84; p = 0.012), respectively. 
The Elixhauser Index also identified a further comor-
bidity related to 30-day mortality: neurological disor-
ders with an OR of 2.22 (CI: 1.45-3.42; with p < 0.001) 
(Table 2).
The variables used in the models proved able to pre-
dict in-hospital and 30 day-mortality with both risk ad-
justment models. APR-DRG showed good discrimina-
tion for in-hospital (C = 0.86) and 30 day-mortality (C 
= 0.82). Similarly, EI predicted in-hospital (C = 0.79) 
and 30 day (C = 0.78) mortality. The calibration (HL 
test) for APR-DRG in-hospital and 30-day mortality 
was 4.81 (p = 0.30) and 4.36 (p = 0.36), respectively, 
and for EI 6.63 (p = 0.25) and 1.81 (p = 0.87), respec-
tively.
Stratification by hospital (15 hospitals: 12 local 
and 3 university) made it possible to compare crude 
and adjusted 30 day-mortality with APR-DRG and 
EI (Figure 1). On one hand, significant differences 
were not found between crude and adjusted outcomes 
for each hospital, nor did crude or adjusted 30 day-
mortality change with EI or APR-DRG. On the other 
hand, using EI, three hospitals (11, 12 and 15 in Fig-
ure 1) proved to have a risk of mortality significantly 
higher than the regional average and two hospitals (8 
and 10) had significantly lower risk of mortality than 
the regional average. Using APR-DRG, statistical dif-
ferences were only confirmed for hospitals 8 and 11. 
Moreover, six hospitals (2, 3, 6, 8, 11 and 14 ) showed 
similar crude and adjusted 30-day mortality values 
with EI. With APR-DRG, six hospitals (2, 3, 7, 8, 12 
and 14) did not show significant differences with re-
spect to each other. Hospitals 2, 3, 8 and 14 did not 
show differences in 30-day mortality with either risk 
adjustment model (Figure 1).
DISCUSSION
Our study evaluated whether risk adjustment tools 
could be useful for risk evaluation of in-hospital and 
30-day mortality in a population of hip replacement 
patients, before surgery. Both models offered advan-
tages and proved useful for identifying centres of ex-
cellence and critical situations. By creating comparable 
groups, adjusted for severity of illness or risk of death, 
they make it possible to assess hospital procedure [13, 
17]. Increasing age and female gender were found to be 
predictors of in-hospital and 30-day mortality with both 
risk adjustment models. Thirty-day mortality has also 
been reported in other studies [20, 21]. Regarding the 
EI model, several comorbidities were found to be pre-
dictive of outcome: congestive heart failure, diabetes, 
chronic lung diseases and liver disease.
The literature confirms that some comorbidities are 
important for short-term outcomes after hip replace-
ment, including mortality [9, 10, 12]. In particular 
Soohoo, et al. identified age, diabetes complications 
and Charlson comorbidity index score among factors 
predictive of complications after HR (including mortal-
ity). Hunt et al. identified comorbidities at admission 
that influence mortality for hip replacement [10, 12]. 
Patients with severe liver disease, cancer, congestive 
heart failure, myocardial infarction and kidney disease 
are particularly at risk of death after hip replacement; 
special efforts to reduce mortality should be focused on 
these groups, and these patients should be informed of 
the risks related to surgery [12]. APR-DRG predicted 
mortality for patients undergoing hip replacement, es-
pecially in cases with age > 75 years, ROD > 2 and male 
gender. Comparing EI with APR-DRG, we found that 
APR-DRG showed slightly better performance in pre-
dicting mortality, at least for HR and also for patients 
with heart failure [22]. On the other hand, EI has the 
advantage of being readily available and free and, in any 
case, it is able to predict even if with lower performance 
than APR-DRG.
Evaluating crude and adjusted 30-day mortality for 
each hospital, some interesting aspects emerged. First, 
mortality values did not significantly differ after risk ad-
justment with either tool; second, we found that crude 
Table 1
Descriptive analysis by age, ROD and gender for in-hospital and 30-day mortality
Patient 
characteristics
In-hospital 
mortality (%)
Total (%) Patient 
characteristics
30-day 
mortality (%)
Total (%)
Age < 65 6 (0.14) 4376 (17) Age < 65 16 (0.37) 4376 (17)
65-74 29 (0.38) 7524 (29) 65-74 67 (0.89) 7524 (29)
75-84 139 (1.47) 9468 (37) 75-84 274 (2.89) 9468 (37)
85+ 167 (3.76) 4437 (17) 85+ 347 (7.82) 4437 (17)
1 167 (0.69) 24 249 (94) 1 443 (1.83) 24 249 (94)
ROD 2 89 (6.82) 1305 (5) ROD 2 152 (11.65) 1305 (5)
3-4 85 (33.86) 251 (1) 3-4 109 (43.43) 251 (1)
Gender M 126 (1.62) 7793 (30) Gender M 278 (3.57) 7793 (30)
F 215 (1.19) 18 012 (70) F 426 (2.36) 18 012 (70)
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and adjusted 30-day mortality were similar in some hos-
pitals (2, 3, 6, 8, 11 and 14 using APR-DRG and 2, 3, 
8, 12 and 14 using EI). These results show that 30-day 
mortality, was not conditioned by the variables consid-
ered. In these hospitals, outcome therefore did not seem 
to be influenced by confounders such as age, gender, 
severity of illness, risk of death or comorbidities. In oth-
er words, it seemed that 30-day mortality of patients, 
regardless of their condition, depended on the hospital 
where they underwent HR, indicating that other factors 
play a role in this outcome. Although it is not possible to 
fully determine the factors that influence this outcome 
or the relative “weight” of each with our data, some hy-
potheses can be advanced. As the literature suggests, 
the overall mortality rate for hip surgery has decreased, 
presumably due to decades of experience, improve-
ments in surgical techniques, anaesthesia and rehabili-
tation [7, 23]. Shorter hospitalization also helps prevent 
postoperative complications [7]. Increased awareness 
about cardiovascular screening and follow-up may also 
help reduce mortality, because most deaths in high-risk 
patients depend on cardiovascular complications [7]. 
Consequently, orthopaedic team experience, surgical 
techniques and the technological level of the hospital 
Table 2
Logistic regression models using APR-DRG and Elixhauser methods by age, ROD and gender for in-hospital and 30-day mortality*
In-hospital mortality
APR-DRG model Odds ratio p [95% CI]
Age 65-74 2.54   0.039 1.05 6.14
Age 75-84 7.63 < 0.001 3.34 17.41
Age 85+ 18.20 < 0.001 7.96 41.43
ROD 2 7.40 < 0.001 5.62 9.63
ROD 3-4 49.70 < 0.001 36.24 68.10
Females 0.64 < 0.001 0.50 0.81
Elixhauser model Odds ratio p [95% CI]
Age 65-74 2.89    0.02 1.19 6.95
Age 75-84 11.08 < 0.001 4.88 25.18
Age 85+ 28.98 < 0.001 12.76 65.79
Females 0.55 < 0.001 0.44 0.70
Chronic pulmonary disease 2.11 < 0.001 1.31 3.42
Diabetes 1.85   0.012 1.20 2.84
Congestive heart failure 9.29 < 0.001 6.09 14.17
Liver disease 5.60 < 0.001 2.84 11.05
30-day mortality 
APR-DRG model Odds ratio p [95% CI]
Age 65-74 2.39   0.002 1.38 4.14
Age 75-84 7.05 < 0.001 4.24 11.74
Age 85+ 19.62 < 0.001 11.79 32.63
ROD 2 4.94 < 0.001 4.05 6.034
ROD 3-4 28.67 < 0.001 21.59 38.08
Females 0.51 < 0.001 0.44 0.61
Elixhauser model Odds ratio p [95% CI]
Age 65-74 2.56 < 0.001 1.48 4.42
Age 75-84 8.70 < 0.001 5.24 14.46
Age 85+ 25.13 < 0.001 15.14 41.70
Females 0.48 < 0.001 0.42 0.57
Chronic pulmonary disease 1.98 < 0.001 1.37 2.84
Diabetes 1.53   0.012 1.10 2.13
Congestive heart failure 6.36 < 0.001 4.37 9.27
Liver disease 3.26 < 0.001 1.75 6.08
Neurological disorders 2.22 < 0.001 1.45 3.42
* Only significant variables are shown
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may be more important for patient “survival” and the 
success of HR operations than clinical condition. Simi-
lar importance seems likely for anaesthesia, in all its as-
pects, before, during and after surgery. Rehabilitation, 
length of stay and postoperative care, including assess-
ment of risk factors (especially cardiovascular) may also 
be of fundamental importance for outcome. 
Another interesting aspect is that in some cases (hos-
pitals 8 and 11 of the Figure 1), the two risk adjustment 
models seem to discriminate differences between 30-
day mortality and average regional mortality in a similar 
and consistent way. In other cases (hospitals 10, 12 and 
15 of Figure 1), we found different discrimination ca-
pacity: the statistical difference from average regional 
mortality seemed to depend on the risk adjustment 
model used, possibly on their different discriminating 
ability. In fact, the results of the C statistic showed a 
slight difference between the two tools. Similarly, a pre-
vious study on risk adjustment for heart failure by Mes-
sina et al. showed some differences between APR-DRG 
and EI. The ability to predict hospital mortality was ac-
ceptable with the former and slightly less with the lat-
ter. Readmission within 30 days for any reason was not, 
however, successfully predicted with either [22]. Other 
factors may of course be involved and further research 
is needed to answer this question.
CONCLUSION
In conclusion, gender, age, EI comorbidities and 
APR-DRG ROD proved to be predictive factors of in-
hospital and 30-day mortality of patients undergoing 
HR. Our study shows the significant importance of risk 
adjustment, suggesting that at least one risk adjustment 
algorithm should be used in patient management.
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